Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Deferred Taxes (2017 - 2025)

Avalo Therapeutics filings provide 9 years of Deferred Taxes readings, the most recent being $131000.0 for Q4 2025.

  • On a quarterly basis, Deferred Taxes rose 14.91% to $131000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $165000.0, a 44.74% increase, with the full-year FY2025 number at $165000.0, up 44.74% from a year prior.
  • Deferred Taxes hit $131000.0 in Q4 2025 for Avalo Therapeutics, up from $10000.0 in the prior quarter.
  • In the past five years, Deferred Taxes ranged from a high of $131000.0 in Q4 2025 to a low of -$62000.0 in Q4 2021.
  • Median Deferred Taxes over the past 5 years was $8000.0 (2022), compared with a mean of $14950.0.
  • The widest YoY moves for Deferred Taxes: up 1366.67% in 2024, down 275.0% in 2024.
  • Avalo Therapeutics' Deferred Taxes stood at -$62000.0 in 2021, then skyrocketed by 112.9% to $8000.0 in 2022, then plummeted by 212.5% to -$9000.0 in 2023, then surged by 1366.67% to $114000.0 in 2024, then increased by 14.91% to $131000.0 in 2025.
  • The last three reported values for Deferred Taxes were $131000.0 (Q4 2025), $10000.0 (Q3 2025), and $16000.0 (Q2 2025) per Business Quant data.